Black Horse Investments

Promentis Pharmaceuticals, Inc. is a biopharmaceutical company based in Milwaukee, Wisconsin, established in 2006. The company specializes in developing therapies for neuropsychiatric disorders, with a focus on addressing glutamatergic imbalance and oxidative stress. Promentis is known for its lead compound, SXC-2023, which targets System xc- to treat multiple conditions, including impulse control disorders and obsessive-compulsive disorder. In addition to SXC-2023, Promentis is also working on other compounds aimed at restoring glutamatergic neurotransmission, which is crucial for improving cortical function and managing various psychiatric disorders, including schizophrenia.